Analysts expect Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to report sales of $67.30 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Amphastar Pharmaceuticals’ earnings. The highest sales estimate is $69.10 million and the lowest is $65.50 million. Amphastar Pharmaceuticals posted sales of $56.67 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 18.8%. The business is scheduled to report its next quarterly earnings results on Monday, May 14th.
On average, analysts expect that Amphastar Pharmaceuticals will report full year sales of $67.30 million for the current year, with estimates ranging from $300.60 million to $325.30 million. For the next fiscal year, analysts anticipate that the business will report sales of $444.78 million per share, with estimates ranging from $426.20 million to $467.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, March 12th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.07 by $0.03. The firm had revenue of $60.40 million during the quarter, compared to the consensus estimate of $60.62 million. Amphastar Pharmaceuticals had a net margin of 1.88% and a return on equity of 4.58%. The company’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.01 earnings per share.
In related news, General Counsel Jason B. Shandell sold 8,661 shares of the business’s stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $19.26, for a total transaction of $166,810.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Stephen B. Shohet sold 7,866 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $18.87, for a total transaction of $148,431.42. Following the transaction, the director now owns 31,982 shares in the company, valued at approximately $603,500.34. The disclosure for this sale can be found here. Insiders have sold 35,677 shares of company stock worth $687,167 in the last quarter. 11.10% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter valued at about $350,000. Millennium Management LLC increased its position in shares of Amphastar Pharmaceuticals by 1,746.9% during the fourth quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock valued at $5,650,000 after buying an additional 277,771 shares during the period. Paloma Partners Management Co purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter valued at about $197,000. Stone Ridge Asset Management LLC purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter valued at about $214,000. Finally, Driehaus Capital Management LLC purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter valued at about $229,000. Institutional investors own 44.82% of the company’s stock.
Amphastar Pharmaceuticals (AMPH) opened at $20.35 on Wednesday. The company has a market cap of $900.21, a PE ratio of 226.11, a PEG ratio of 1.16 and a beta of 1.46. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.86 and a current ratio of 3.08. Amphastar Pharmaceuticals has a one year low of $12.05 and a one year high of $20.45.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.